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SIGMA-1 RECEPTORS: POTENTIAL THERAPUETIC TARGETS FOR 
SUBSTANCE USE DISORDERS 
 
JOHN AMOS TOMS III 
ABSTRACT 
 
Substance use disorders are a prominent issue within the United States that must be 
addressed given the high prevalence, economic cost, and negative health consequences of 
these medical conditions. Current treatments are inadequate due to the limited success of 
behavioral therapies and the lack of pharmacological interventions geared towards 
preventing the neuroplastic changes initiated by substances of abuse that lead to 
addiction. Sigma-1 receptors represent promising pharmacological targets for treatment 
of substance use disorders involving cocaine and methamphetamine use. A review of 
recent studies suggests that sigma-1 receptors contribute to the underlying mechanisms of 
action utilized by cocaine. Yet the use of sigma-1 receptor antagonists shows promising 
results of mitigating the physiological effects induced by cocaine. In contrast to cocaine, 
sigma-1 receptors have yet to be linked to the underlying mechanisms of action utilized 
by methamphetamine. However studies indicate that the use of sigma-1 receptors 
agonists creates a neuroprotective effect against the physiological effects induced by 
methamphetamine. Currently the pharmacological targeting of sigma-1 receptors is not 
utilized to treat substance use disorders. A review of literature was conducted in order to 
elucidate the mechanistic role that sigma-1 receptors play in mediating the physiological 
effects induced by cocaine and methamphetamine that lead to addiction. Using this 
 v 
information, the potential use of sigma-1 receptors as therapeutic targets was discussed in 
order to provide insight about the benefits and limitations of utilizing such an 
intervention as treatment for substance use disorders involving cocaine and 
methamphetamine use.   
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 1 
INTRODUCTION 
 
History of Substance Regulation 
 
In order to standardize drug policy and allow better public health outcomes, United States 
president, Richard Nixon, signed the Controlled Substance Act (CSA) in 1970. Since 
enactment of this federal drug policy, the importation, manufacture, possession, use, and 
distribution of controlled substances has become more strictly regulated. Substances have 
since been classified into five “Schedules” or classifications based on their potential for 
abuse or dependency and on the accepted medical benefits they may provide (Table 1).1  
 
Table 1: Controlled Substance Schedules  
 
Definition of the five substance classifications (C-I to C-V) and example drugs for each 
class. Taken from Ahrnsbrak.1 
 
 
With establishment of this classification, the United States Drug Enforcement 
Administration (DEA) is capable of limiting both access to a particular substance and its 
supply via production quotas. Despite these more stringent regulations, The National 
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Survey on Drug Use and Health (NSDUH) reported in 2016 that roughly 28.6 million 
Americans had used illicit drugs within the year.1 With the repetitive use of illicit drugs, 
the chance of falling into a state of dependency on these substances is increased, often 
leading to the development of a substance use disorder.  
 
The Prevalence and Cost of Substance Use Disorders 
 
According to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), a 
Substance Use Disorder (SUD) is a combination of cognitive, behavioral, and 
physiological symptoms that indicate that an individual continues using a particular 
substance despite significant substance-related problems.2 Substance use disorders are a 
prominent problem within the United States that have been shown to not only negatively 
affect the user but to also indirectly cause detrimental consequences to the rest of 
society.1,3-6 
 
In 2016 alone, roughly 20.1 million Americans, ages 12 or older, had been diagnosed 
with a substance use disorder related to their use of alcohol or illicit drugs. In regards to 
demographics affected, Americans, ages 18 to 25, represented the demographic most 
likely to develop a SUD (Figure 1).1 According to the National Institute on Drug Abuse, 
men are more likely than women to both use an illicit drug and use an illicit drug in way 
that resulted in an emergency department visit or overdose.  Women, on the other hand, 
are more susceptible to drug craving and relapse, key phases of addiction. Despite these 
differences however, both sexes are equally likely to develop a SUD. 3   
 3 
 
Figure 1: Substance Use Disorder Percentage of Total US Population Among People 
Aged 12 or Older, By Age Group. From the National Survey on Drug Use and Health, 
2016.1 
 
Substance use disorders have been linked to a variety of adverse health outcomes and 
comorbidities. With repetitive substance use, users often acquire the symptoms of 
addiction where as a result they are at a higher likelihood of developing other severe 
health consequences such heart or lung disease, cancer, and sexually transmitted 
diseases.4 Additionally high prevalence of anxiety disorders, such as generalized anxiety 
disorder, panic disorder, and post-traumatic stress disorder, along with mental health 
disorders, such as depression, bipolar disorder, and attention-deficit hyperactivity 
disorder, co-occur in people diagnosed with substance use disorders.5  
 
With such a high population prevalence and negative health consequences, substance 
abuse disorders have exacted over $740 billion from the United States annually in costs 
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related to crime, lost work productivity, and health care.6 It is clear given these statistics 
that substance use disorders are a prominent issue that must be addressed. 
 
 
Function and Organization of the Mesolimbic Reward Pathway  
 
The mesolimbic dopaminergic pathway or mesolimbic reward pathway is an area of the 
brain that plays a central role in motivation, reward and reinforcement processing, and 
goal-oriented behaviors that is altered by substances of abuse.7 While this pathway 
consists of a variety of different subcortical structures, the most prominent structures 
most associated with pleasure, reward, and addiction are the ventral tegmental area 
(VTA), the nucleus accumbens (NAc), the amygdala, and the prefrontal cortex (PFC).7,8 
All of these structures coordinate with each other to provide the sensation of reward yet 
each serves a distinct role within this pathway.  
 
The VTA is a dopamine-rich nucleus located in the ventral portion of the midbrain where 
dopaminergic neurons generate dopamine, the neurotransmitter crucial for mitigating the 
reward response.7 The nucleus accumbens is located in the basal forebrain and serves the 
purpose of associating pleasurable experiences with certain motor behaviors, such as 
eating, that creates positive reinforcement for such motor behaviors to be repeated.7 The 
amygdala is an almond-shaped group of nuclei situated in the telencephalon portion of 
the brain involved with a variety of cognitive functions such as emotion, memory, 
learning, attention, and perception. Within the mesolimbic pathway, the amygdala 
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establishes a reward value to a given stimuli and any events known to serve as predictors 
of this stimuli.9,11 Lastly the prefrontal cortex is the region of the brain associated with 
complex cognitive behavior, decision making, personality expression, and social 
behavior. Within the mesolimbic pathway, the PFC is involved with the integration of 
goals and reward information where it is recruited by motivationally relevant events and 
stimuli acting as predictors of these events and mediates both whether a behavioral 
response will be emitted and to what degree this response will occur at.10  
 
Structurally within the brain, the mesolimbic pathway originates begins at the VTA 
where dopamine is generated within the dopaminergic neurons. From here axons of these 
neurons extend out of the VTA and terminate in the NAc, amygdala, and PFC. When the 
experience of a reward occurs, either naturally through activities such as eating or sex or 
artificially through drugs, increased levels of dopamine are present within the VTA and 
released into the NAc, amygdala, and PFC where the neurotransmitter binds to 
postsynaptic dopamine receptors, initiating the respective function of each subcortical 
structure and consequently stimulating the feeling of pleasure.11  
 
Overview of the Mechanism of Drug Addiction 
 
While each drug of abuse has its own unique mechanism of action, the general effect is 
that an increase of dopamine within the mesolimbic dopaminergic pathway of the brain is 
initiated upon use of a drug, stimulating a feeling of euphoria and exerting the initial 
positive reinforcement for a user to continue usage.12  With repetitive usage, the brain 
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begins to undergo neuroplastic alterations leading to increased reactivity to drug cues, 
reduced sensitivity to non-drug rewards, weakened self-control, and increased 
sensitivity to stressful stimuli.13At this point, usage of a drug becomes beyond a matter 
a choice as these alterations, compounded with the negative reinforcement of 
withdrawal symptoms, lead users to not only continue their substance abuse but to also 
increase their frequency of use and dosage of the substance merely to maintain a normal 
homeostatic state.14 With this increased frequency of use and dosage of a particular 
substance, a user increases their likelihood of suffering from a substance overdose and 
potentially death. Notably, overdose-related deaths have nearly doubled since the early 
2000’s, highlighting the need for intervention (Figure 2).  
 
 
Figure 2: Total U.S. Drug Deaths 1990-2017. This figure demonstrates the increasing 
trend of deaths in the United States caused by drug overdose. From the National 
Institute on Drug Abuse, 2017.15 
 
Given that repeated drug usage is known to cause the neuroplastic changes, it is 
believed that therapeutic inventions aimed at managing and reversing these changes 
could aid in alleviating symptoms of addiction.12 However the vast variety of drugs 
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which utilize different mechanisms of action makes successful treatment of addiction 
challenging. Current pharmacological interventions available for use are limited in their 
efficacy and often cause significant adverse side-effects.16 With no pharmacological 
intervention established as being completely effective, it is crucial that new 
mechanisms of therapy are investigated in order find a solution to this problem.  
 
The Potential Role of Sigma-1 Receptors 
 
Reviewing previous literature, it has become apparent that sigma receptors may play a 
role in mitigating the psychostimulant effects of drugs of abuse. Within the human 
body, two types of sigma receptors have been identified: the sigma-1 receptor (σ1R) 
and the sigma-2 receptor (σ2R). While sigma-2 receptors may contribute to mediating 
these psychostimulant effects, the sigma-1 receptor, an endoplasmic reticulum 
chaperone protein that serves as inter-organelle signaling modulator, is the predominant 
sigma receptor responsible for this action.17 Initially thought to be a type of opioid 
receptor, this receptor is now recognized to be distinct from the opioid class due to its 
ability to bind with high affinity to several classes of chemically-unrelated ligands 
ranging from neurosteroids to antipsychotics to psychostimulants such as cocaine and 
methamphetamine.17,18 Additionally these receptors are predicted to regulate a number 
of neurotransmitter systems including the glutamatergic, dopaminergic, serotonergic, 
noradrenergic, and cholinergic systems; systems that are known to interact with the 
reward pathways of brain.18 Having a widespread distribution throughout the central 
nervous system in addition to possessing the ability to bind a broad range of 
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chemically-unrelated ligands and regulate prominent neurotransmitter systems, sigma-1 
receptors have been considered as potential therapeutic targets to modulate mood 
disorders and amnesic and cognitive deficits associated with the drugs of abuse cocaine, 
methamphetamine, and 3,4-methylenedioxymethamphetamine (MDMA).19  
 
While initial research concerning sigma-1 receptors as potential therapeutic targets for 
substance use disorders associated with these drugs of abuse seems promising, 
significant speculation still exists concerning their specific mechanism of action and 
which effects may result should these receptors be targeted. It is clear that further 
investigation concerning these areas of speculation is needed in order to help elucidate 
the potential of sigma-1 receptors to mitigate the detrimental effects of substances of 
abuse. Given this, a review of literature was conducted in order to evaluate the 
mechanistic role that sigma-1 receptors play in mediating the physiological effects 
induced by cocaine and methamphetamine that lead to addiction. With this information, 
the potential use of sigma-1 receptors as therapeutic targets will be discussed in order to 
provide insight about the benefits and limitations of utilizing such an intervention as 
treatment for substance use disorders involving cocaine and methamphetamine.   
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LITERATURE REVIEW 
Sigma Receptors and Cocaine 
Overview of Cocaine 
 
Cocaine is a central nervous system stimulant extracted from the Erythroxylon bush that 
is found primarily in the South American countries of Peru, Bolivia, and Columbia.20 
When smoked, injected, or snorted, cocaine increases energy and alertness and stimulates 
a feeling of euphoria; all while simultaneously increasing body temperature, heart rate, 
and blood pressure.20,21 While more commonly known as a substance of abuse, cocaine, 
due to its rapid absorption, analgesic properties, and vasoconstrictive ability, has been 
utilized as a local anesthetic in ear, nose and throat operations.21 While cocaine provides 
this medical utility, its high potential of abuse and adverse side effects have led to its 
classification as a Schedule II substance that is highly regulated by the United States 
DEA (Table 1).  
 
The Prevalence and Impact of Cocaine Usage 
 
Cocaine is a widely used drug that has many negative aspects associated with it. In 2017, 
the United States Central Intelligence Agency identified the United States as the world’s 
largest consumer of cocaine.22 The National Survey on Drug Use and Health showed that 
nearly 38 million Americans aged 12 or older reported using cocaine at some point in 
their lifetime with about 913,000 Americans meeting the DSM-5 criteria for dependence 
or abuse of cocaine.23  According to the National Center for Health Statistics, roughly 
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forty percent of drug misuse or abuse-related emergency department visits were 
documented to involve cocaine. From 2010 to 2017 alone there has been a 3.5- fold 
increase in the total number of deaths due to cocaine (Figure 3).15,23 
  
 
 
Figure 3: Number of Deaths Involving Cocaine. Bar chart showing the total number of 
U.S. overdose deaths involving cocaine from 2002 to 2016, with provision data for 2017. 
From the National Institute on Drug Abuse, 2017.15 
 
Beyond these statistics, various negative health outcomes are associated with cocaine 
usage.24 Any route of administration can lead to the absorption of toxic levels of cocaine 
that can cause heart attacks, strokes, or seizures potentially leading to sudden death.24 
Additionally both chronic and recreational users have been showed to develop cognitive 
deficits specifically with working memory, declarative memory, and attention.25,26 While 
the short term adverse effects of erratic and violent behavior and panic attacks may be 
incentive for users to stop usage, often the withdraw symptoms of fatigue, difficulty 
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concentrating, insomnia, depression, and suicidal thoughts can be motivation for the 
continued usage of this drug.26,27  
 
The Need for Cocaine Addiction Treatment 
 
Despite the detrimental effects of cocaine usage, users who cease their cocaine 
consumption can recover entirely and attain similar attention, memory, and global 
cognitive performance as those who have never partaken in cocaine consumption.25 
However while the benefits of ending cocaine consumption are clear, often this action is 
difficult for users due to the high reinforcing effects of cocaine.26  
 
Current treatment options for people who suffer from substance use disorders involving 
cocaine addiction include behavioral treatments, such as contingency management which 
utilizes motivational incentives to help people avoid cocaine usage and cognitive-
behavioral therapy which helps patient develop critical skills that support long-term 
abstinence.23 However roughly 1 in 4 people relapse back to weekly cocaine usage within 
a year following treatment.28,29 It is therefore clear that behavioral treatments, while 
effective, are still limited in their efficacy.  
 
Currently there are no pharmacological interventions approved by the U.S. Food and 
Drug Administration for cocaine addiction treatment. Yet it is hypothesized that a 
combination of behavioral therapy and pharmacotherapy will produce the most effective 
approach for treatment.30 Given that studies have shown that complete cessation of 
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cocaine leads to the reversibility of cognitive deficits caused by moderate exposure, it is 
necessary for pharmacotherapies to be developed in order to better assist user cessation.25  
 
Overview of the Mechanism of Cocaine 
 
Upon administration, cocaine acts upon the dopaminergic neurons extending from the 
VTA to the nucleus accumbens, the initiator of the feeling of reward within the 
mesolimbic reward pathway.31 Cocaine triggers a variety of different actions within the 
neuronal synapse and the brain. One of the primary short-term actions of cocaine is that it 
binds and blocks the dopamine transporter (DAT), a transmembrane protein responsible 
for the reuptake of dopamine released into the synaptic cleft back into the pre-synaptic 
axon terminal. As a result of blocking the DAT on these pre-synaptic axon terminals, 
cocaine both increases the magnitude and decreases the decay rate of extracellular 
dopamine within the synaptic cleft, allowing for increased post-synaptic dopamine 
receptor binding (Figure 4).31 This augmented synaptic transmission leads to an increase 
in neuronal firing within the nucleus accumbens, consequently invoking a more 
pronounced feeling of reward within the drug user.   
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Figure 4: Effects of Cocaine on the Dopamine Transporter. Cocaine binds and block 
DAT in the neuronal synaptic cleft, leading to an increase in the extracellular dopamine 
concentration. This action stimulates an increased feeling of euphoria as more dopamine 
receptor binding is initiated. From Penberthy et al., 2010.31 
Cocaine additionally possesses the ability to increase the binding capability of itself to 
DAT by altering the conformation of the transporter on the pre-synaptic axon terminal 
within the synapse. Upon administration, cocaine alters the TM6a domain of DAT, a key 
domain involved in DAT binding, leading to an increase in the accessibility of the 
transporter for binding.32 Therefore in regards to the relationship between cocaine and 
DAT, cocaine possesses the ability to both increase the binding capability of itself to 
DAT and effectively block this transporter. 
 
Beyond this primary short-term action, cocaine additionally temporarily increases the 
magnitude, duration, and even frequency of spontaneously occurring dopamine release 
events termed “transients”.33,34 This action on dopamine transients, which are known to 
generate a sense of reward for predictive stimuli and consequently help direct behavior, is 
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thought to play a crucial role in the development of the addictive behavior associated 
with cocaine.35,36 
 
With chronic usage of cocaine, more long-term effects are invoked as the brain begins to 
undergo neuroplastic changes to adjust to the perturbations caused by cocaine.37 For 
example, cocaine upon administration increases voltage-gated K+ currents in medium 
spiny neurons within the nucleus accumbens. By increasing voltage-gated K+ currents, 
cocaine causes the medium spiny neurons to become hyperpolarized, reducing the ability 
of these neurons to fire within the nucleus accumbens and stimulate a feeling of reward 
for the user.38 With chronic usage, the repetitive depression of medium spiny neuronal 
firing leads to the activation of the cyclic adenosine monophosphate (cAMP)-dependent 
pathway.37 Through this pathway, a variety of intracellular signaling proteins including 
membrane ion channels, enzymes, and transcription factors are activated where they then 
initiate changes in gene expression.39,40 As a result of this process, medium spiny neurons 
within the nucleus accumbens adjust to a lower baseline firing rate that is maintained 
long after cocaine usage.38,41 This reduced baseline firing rate within the nucleus 
accumbens causes an overall decrease in the sensitivity of the mesolimbic reward 
pathway.38 
 
With a decrease in the sensitivity of the mesolimbic reward pathway, an individual is 
unable to experience the same level of reward from natural reinforcers as experienced 
prior to cocaine usage. It is at this stage that individuals then begin to experience the 
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common withdrawal symptoms associated with drug addiction as mesolimbic 
dopaminergic pathway stimulation and the associated sensation of reward are 
decreased.42 In an attempt to reduce these withdrawal symptoms, individuals often 
continue their usage of cocaine, potentially leading to the development of a substance use 
disorder.   
 
Relationship Between Sigma-1 Receptors and Cocaine 
 
Given that cocaine has been demonstrated to bind to these receptors at physiologically 
relevant concentrations,  further studies have been conducted in order to investigate the 
potential relationship of sigma-1 receptors and cocaine.43 From recent animal studies, 
sigma-1 receptors were shown to increase the ability of cocaine to bind to DAT, mediate 
the dampening effect of cocaine on spiny neuronal firing in the nucleus accumbens, and 
mediate the increase in locomotor activity associated with cocaine use.32,38,46,48,50  
 
Given that cocaine possesses the capability to not only bind and block DAT at the 
neuronal synapse but to also increase its own ability to bind these transporters, further 
studies were conducted in order to see if sigma-1 receptors played a role in mediating this 
effect. Upon activation by agonists such as (+)-pentazocine or 2-(4-Morpholinethyl) 1-
phenylcyclohexanecarboxylate hydrochloride (PRE-084), sigma 1 receptors may increase 
the amount of DAT receptors available for cocaine binding, allowing more cocaine to 
bind and initiate its effects (Figure 5).32  
 
 16 
 
Figure 5: Regulation of DAT Function by σ1R Agonists in Native Tissues and 
Transfected Cells. A and B, rat striatal slices were incubated with σ1R agonists, washed, 
and homogenized to measure [3H]WIN35428 binding. Shown are representative binding 
curves with triplicate samples and summarized Bmax values in the bar graph. Both the 
Bmax and percentage of binding of [3H]WIN35428, a cocaine analog, were significantly 
increased compared to the vehicle in striatal homogenates pre-incubated with 10 uM (+)-
pentazocine ((+)Pent) or 10 uM PRE-084. *, p<0.05. N=4-5 experiments. From Hong et 
al., 2017.32  
 
Furthermore, sigma-1 receptors, rather than increase DAT expression levels, are capable 
of forcing pre-existing DATs from inward-facing conformation where they are unable to 
be bound into an outward-facing conformation where they can be bound by cocaine. In 
order to accomplish this, it is speculated that sigma-1 receptors upon activation by a 
agonist such cocaine dissociates into dimers and monomers where the monomers are 
capable of interacting with DAT.32 Given that sigma-1 receptors are proven to bind to 
cholesterol, upon associating with DAT, they may also increase the cholesterol content of 
the microdomains surrounding the transporter.32,44 This increased cholesterol content then 
hinders the movement of TM1a, a domain necessary for DAT to transition into the 
inward-facing conformation.45 It is therefore speculated that upon activation sigma-1 
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receptors are capable of stabilizing the outward-facing conformation of DAT where it can 
then bind cocaine (Figure 6).  
 
 
 
 
Figure 6: Schematic Summarizing the Modulation of DAT Conformation and 
Cocaine Binding by Sigma-1 Receptors. In the left panel, binding of σ1R agonists 
facilitates dissociation of σ1R multimers into monomers. In the right panel, these 
monomers dynamically interact with DAT to promote an outward-facing conformation of 
DAT, thus enhancing cocaine binding and potentiating cocaine's behavioral response. 
From Hong et al., 2017.32 
 
In addition to increasing the number of DATs available to bind, there is strong indication 
that sigma-1 receptors  assist with mediating the cocaine-induced neuronal firing 
depression in the nucleus accumbens caused by an increase in K+ current within the 
nucleus accumbens medium spiny neurons.38,46 Sigma-1 receptors are capable of 
associating with subfamily A member 2 potassium voltage-gated (Kv1.2) channels within 
the nucleus accumbens medial shell.47 Upon administration of cocaine, binding between 
sigma-1 receptors and Kv1.2 channels significantly increased (Figure 7A-B). In addition, 
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translocation of sigma-1 receptors from the endoplasmic reticulum of these neurons to the 
plasma membrane is also increased (Figure 7C).38 
 
 
 
 
 
Figure 7. Cocaine Enhances the Interaction between Sigma-1 Receptors and Kv1.2 
Channels and Increases Sig-1R Protein Levels at the Plasma Membrane.  
A–B: Neuroblastoma-glioma hybrid cells (NG108-15) were transfected with pcDNA3.1-
Sig-1R-V5-His and pCMV6-Kv1.2 plasmids to overexpress Sig-1R-V5 and Kv1.2, 
respectively. Sig-1R-V5- and Kv1.2-overexpressing NG108-15 cells were treated with 
different doses of cocaine as indicated for 6 hr. Cell extracts were then 
immunoprecipitated with the anti-Kv1.2 antibody followed by immunoblotting using 
anti-Kv1.2 or anti-V5 antibody, respectively. The protein level of endogenous Sig-1Rs 
was detected using anti-Sig-1R antibody, and ERK1/2 was used as the loading control. 
Cocaine increases Sig-1R and Kv1.2 binding (One-way ANOVA: treatment, p < 0.001). 
C: NG108-15 cells were transfected with pEYFP-N1, pEYFP-C1-Sig-1R, or pEYFP-N1-
Sig-1R to express yellow fluorescent protein (YFP), YFP-Sig-1R, or Sig-1R-YFP, 
respectively. Cocaine (3 µM, 6 hr) increases Sig-1Rs at the plasma membrane by ∼80%. 
Adapted from Kourrich et al., 2013.38 
C 
 19 
 
With this increased binding with K1.2v channels and translocation to the plasma 
membrane, sigma-1 receptors are capable of increasing K+ conductance in the nucleus 
accumbens, mediating the neuronal hypoactivity in the nucleus accumbens occurs with 
cocaine usage (Figure 8).38,48  
 
 
Figure 8: Schematic Representing the Cocaine-induced Interaction of Kv1.2 
Channels and Sigma-1 Receptors. Cocaine activate sigma-1 receptors which are shown 
to upregulate K+ channels on the plasma membrane by binding to Kv1.2 channels and 
trafficking them from the endoplasmic reticulum (ER) to the plasma membrane. An 
increase in Kv1.2 channels produces an increase in K+ conductance, leading to a 
decrease in the neuron firing rate in the nucleus accumbens. From Kourrich et al., 2013.38 
 
Lastly, sigma-1 receptors mediate the increase in locomotor activity that is associated 
with chronic cocaine usage. Repetitive cocaine usage causes upregulation of early genes 
which enact long-lasting changes to gene and protein expression. Sigma-1 receptor gene 
and protein expression levels are significantly upregulated within the mesolimbic 
pathway with prolonged cocaine use.49 Additionally, increased sigma-1 receptor gene and 
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protein expression levels are linked to increased locomotor activity associated with 
cocaine (Figure 9).50 These findings provide further indication that sigma-1 receptors 
play a role in mitigating the behavior adaptions seen with chronic cocaine usage.    
 
 
Figure 9: Association Between Cocaine-induced Locomotor Activity and Increased 
Sigma-1 receptor Gene and Protein Levels in the Brain. The locomotor behavior data 
and the molecular expression data for sigma-1 receptors were plotted on the same graphs 
for the cocaine treatment group. This graph demonstrates that prolonged cocaine usage 
lead to increased sigma-1 receptor gene and protein expression which was associated 
with increased locomotor activity. From Liu and Matsumoto, 2008.50  
 locomotor behavior data and the molecular ex 
 
The Effects of Sigma-1 Receptor Antagonists  
 
Given that sigma-1 receptors mediate the physiological effects of cocaine, additional 
studies evaluated whether sigma-1 receptors can be targeted and blocked in order to 
mitigate the cocaine-induced effects. These studies showed that numerous novel 
compounds can be utilized to antagonize sigma-1 receptors and the effects they mediate. 
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As described earlier, sigma-1 receptors upon activation dissociate into dimers and 
monomers, associate with DAT, and cause DAT to take on an outward-facing 
conformation where it can then bind cocaine (Figure 6). Knowing this mechanism, 
further analysis has been conducted to examine whether a selective sigma-1 receptor 
antagonist could prevent this initial dissociation. While use of the sigma-1 receptor 
agonist, (+)- Pentazocine, significantly increased dimeric and monomeric sigma-1 
receptor fractions, the use of the antagonist, 3-(2-(azepan-1-yl)ethyl)-6-(3-
fluoropropyl)benzo [d] thiazol-2(3H)- one hydrochloride (CM304), was able to prevent 
this dissociation (Figure 10). By preventing this dissociation, no upregulation of the 
number of DAT available for cocaine to bind occurs, decreasing the ability of cocaine to 
induce its effects.32 
 
 
Figure 10: Effects of Sigma-1 Receptor Ligands on Sigma-1 Receptor 
Multimerization. Cells expressing σ1R were incubated with ligands in culture medium 
at 37 °C for 1 h, then lysed with GDN lysis buffer and subjected to PFO-PAGE. FLAG 
antibodies detected multiple bands, corresponding to monomer, dimer, and high-order 
oligomers of σ1R. Shown are quantified results of multimeric band signals. The fraction 
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of monomer out of total signals (including monomer, dimer, and multimer) in each 
treatment was calculated and normalized to that of vehicle. (+)-Pentazocine (Pent) 
significantly increased monomeric σ1R fractions while CM304 prevented sigma-1 
receptor multimer dissociation (**, p<0.01). One-way ANOVA and post-hoc Dunnett’s 
test were performed. Adapted from Hong et al., 2017.32 
  
 
Looking at the involvement of sigma-1 receptors in mediating the dampening effect of 
cocaine on neuronal firing rate within the nucleus accumbens, research shows that the use 
of the selective sigma-1 receptor antagonist, 1-[2-(3,4-dichlorophenyl)ethyl]-4-
methylpiperazine (BD1063) is capable of blocking this action of cocaine. Pre-incubation 
of BD1063 into the nucleus accumbens rescues the cocaine-induced reduction in 
neuronal spike frequency (Figure 11).38 By upholding baseline neuronal firing rates 
within the nucleus accumbens, BD1063 prevents changes to the sensitivity of the 
mesolimbic reward pathway allowing natural reinforcers to continue to provide a sense of 
reward.  
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Figure 11: Effects of BD1063 on Cocaine-Induced Reduction of Nucleus Accumbens 
Neuronal Firing Frequency. Nucleus accumbens firing frequency was measured 
according to spike frequency. Within each test, cells within the nucleus accumbens were 
first incubated with an injection of either saline (sal) or BD1063 (BD) and then were 
injected with either saline or cocaine (coc). Spike frequency was significantly lowered in 
the saline and cocaine test but was rescued when cells were preincubated with BD1063 
prior to cocaine administration. N= 8–13 cells per group; 3–6 mice per group. For all 
tests, one-way ANOVA was performed, *, p<0.05; **, p<0.01; ***, p < 0.001.  
From Kourrich et al., 2013.38 
 
In addition to preventing the reduction in nucleus accumbens neuronal firing rate, 
BD1063 also moderates the locomotor activity effects that are induced by cocaine. 
Utilization of BD1063 significantly reduces the increase in locomotor activity that is seen 
with repetitive cocaine administration (Figure 12).50 These results serve as further 
indication that antagonizing sigma-1 receptors can attenuate both the desensitizing effects 
on the mesolimbic reward system as well as the psychomotor effects caused by cocaine.    
 
 
 
Figure 12: Effects of BD1063 on Cocaine-Induced Locomotor Activity. Mice received 
either an injection of saline (Sal) or BD1063 (BD). Following this injection, they were 
then administered either an injection of saline or cocaine (Coc). Their locomotor activity 
was then measured as cm/60 min. N= 7-12 mice. Saline administered in combination 
with cocaine (Sal + Coc) increased locomotor activity significantly (***, p<0.001). 
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Administration of BD1063 with Cocaine (BD+Coc) reduced the magnitude of increase 
induced by cocaine. Adapted from Liu and Matsumoto, 2008.50   
 
Beyond CM304 and BD1063, numerous other compounds also act as antagonists for 
sigma-1 receptors (Table 2). Interestingly these antagonists exert none of the previously 
mentioned effects unless cocaine is administered. These compounds all interact with 
sigma-1 receptors with high selectivity and protect against the locomotor and toxic 
effects induced by cocaine.51 Given this, these compounds in addition to CM304 and 
BD1063 show promise to serve as a component of a pharmacological intervention for the 
treatment of substance use disorders involving cocaine should they be deemed safe and 
effective by clinical trials.51 
Table 2: Selective Sigma-1 Receptor Antagonists 
Ligand Chemical Name 
AC927 N-phenethylpiperidine 
BD1047 N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-
(dimethylamino)ethylamine 
BMY 14802 a-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperzine-butanol 
CM156 3-(4-(4-cyclohexylpiperazin-1-yl)butyl)benzo [d]thiazole-2(3H)-thione 
MS-377 (R)-(+)-1-(4-chlorophenyl)-3-[4-(2-methoxyethyl)piperazin-1-yl] 
methyl-2-pyrrolidinone 
NE-100 N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl]ethylamine 
SM21 Tropanyl 2-(4-chlorophenoxy)butanoate 
SM79 6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[ d]oxazol-
2 (3H)-one 
A list of compounds in addition to CM304 and BD1063 that are currently known to 
interact with sigma-1 receptors with high selectivity and to protect against the locomotor 
and toxic effects induced by cocaine. From Matsumoto, 2009.51 
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Sigma Receptors and Methamphetamine 
Overview of Methamphetamine 
 
Methamphetamine is a central nervous stimulant developed in the 20th century from 
amphetamine. Structurally methamphetamine only differs from amphetamine by a single 
methyl group. However this difference permits a larger percentage of methamphetamine 
to remain in the body unchanged, allowing a longer duration of action compared to 
amphetamine.52 When swallowed, snorted, injected, or smoked methamphetamine causes 
the short-term effects of increased wakefulness and physical activity, increased feeling of 
euphoria, faster breathing, decreased appetite, and increased body temperature.53 In 
regards to its medical benefits, methamphetamine limitedly serves as treatment for 
attention deficit hyperactivity disorders and narcolepsy as well as a short-term component 
of weight-loss treatments.53 However given its high potential of abuse and the variety of 
severe adverse effects it causes, methamphetamine is highly regulated as a Schedule II 
substance (Table 1).  
 
The Prevalence and Impact of Methamphetamine Usage 
 
According to the National Survey on Drug Use and Health over 12 million people, ages 
12 and older, have tried methamphetamine at least once.53 As a result of this, 
methamphetamine is currently recognized as the most commonly used drug of abuse 
behind marijuana.53 Given its highly addicting yet short lasting effects, users tend to 
indulge in this drug in a “binge and crash” pattern where they self-administrated 
methamphetamine repetitively, typically multiple times daily and often for several days 
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in a row in order to maintain a high sensation.52  With long-term usage of 
methamphetamine, users are prone to develop severe dental problems, anxiety, paranoia, 
mood disturbances, and violent behavior. Additionally, repetitive usage causes cognitive 
and memory deficits, reduced coordination, impaired verbal learning, and other 
cardiovascular, pulmonary, and neurological issues.53,54 According to the 2017 National 
Drug Threat Assessment, methamphetamine is responsible for 85-90% of deaths related 
to stimulant drug use. Upon cessation of drug usage, users are often subjected to strong 
withdrawal symptoms of severe depression, fatigue, and psychosis where delusions and 
hallucinations are common and can occur intermittently for several months following 
usage.53,54 Beyond these health consequences, methamphetamine additionally causes an 
economic burden between $16.2 and $48.3 billion in the United States due to the inflicted 
costs associated with premature mortality, health care services, lost productivity, and 
crime.56 
 
The Need for Methamphetamine Addiction Treatment 
 
Unlike cocaine where cessation from the drug usually leads to full recovery, studies 
indicate that only some of the neurobiological effects of chronic methamphetamine use 
are partially reversible with drug cessation.53 It is therefore crucial that treatment is 
provided promptly to lessen the permanent cognitive and motor skill damage 
methamphetamine can inflict on its users.  However current treatments for 
methamphetamine addiction are limited.  
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Currently behavioral therapies remain the primary treatment for methamphetamine 
addiction. Cognitive-behavioral therapy which helps patients to recognize, avoid, and 
cope with the situations in which they are most likely to use drugs remains the forefront 
treatment.53 Other therapies utilizing motivational incentives to encourage abstinence 
from drug usage are also utilized.57 While these types of treatments are effective to an 
extent, roughly 61% of methamphetamine users will relapse within 1 year of finishing 
substance abuse treatments such as these.58  
 
In regards to pharmacological interventions, there are currently no medications approved 
by the FDA to treat substance use disorders involving methamphetamine addiction.53 
Current medications, such as Bupropion and Naltrexone, often prescribed for 
methamphetamine users focus on the initiation of abstinence and prevention of relapse 
and are primarily used to mitigate the withdrawal symptoms users experience.54 However 
these medications have limited utility as treatment and none target the underlying 
mechanisms that methamphetamine enacts within the body that cause dependence.   
 
Given the limited efficacy of current treatments, it is clear that further investigation is 
necessary to develop treatments more capable of assisting users in overcoming the 
addicting effects of methamphetamine.  
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Overview of the Mechanism of Methamphetamine 
 
Similar to cocaine, methamphetamine acts upon the dopaminergic neurons extending 
from the VTA to the nucleus accumbens.51 Reviewing studies on methamphetamine, it is 
evident that it is capable of enacting a variety of different actions within the neuronal 
synapse and the brain where both short- and long-term effects can occur with usage. 
 
Short-term, methamphetamine similarly to amphetamine is responsible for increasing the 
extracellular concentrations of dopamine within the nerve synapse.51 Upon use, 
methamphetamine acts as a substrate for the DAT and enters into the pre-synaptic nerve 
terminal. Once inside the terminal, it blocks the action of the vesicular monoamine 
transporter 2 (VMAT2), a transporter responsible for sequestering cytoplasmic dopamine 
into vesicles for storage and subsequent release.52,59 With inhibition of VMAT2, 
cytoplasmic dopamine levels increase within the pre-synaptic nerve terminal. Beyond its 
interaction with VMAT2, methamphetamine acts upon DAT where it initiates a reverse 
transport of dopamine out of this transporter into the synaptic cleft.59,60 By invoking an 
increase in cytoplasmic dopamine levels and an increase in the transport of dopamine out 
nerve synapse, methamphetamine is capable of subsequently increasing the extracellular 
concentration of dopamine within the nerve synapse. This increase in the extracellular 
concentration of dopamine allows more dopamine receptor binding to occur, initiating 
more dopaminergic neuron firing within the nucleus accumbens that stimulates the 
euphoric feeling associated with the drug use (Figure 13). 
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Figure 13: Mechanism of Methamphetamine. Upon entering into the pre-synaptic 
nerve terminal, methamphetamine blocks the vesicular monoamine transporter 2, 
increasing the cytoplasmic concentration of dopamine levels and initiates the reverse 
transport of dopamine through DAT. Through these actions, methamphetamine is capable 
of increasing extracellular concentrations of dopamine in the nerve synapse. From Kish, 
2008.52 
 
 
With long term usage of methamphetamine, several major adaptations begin to occur. In 
regards to transporters, both DAT and VMAT2 levels are significantly decreased.61-63 
With a decrease in these transporters, cytoplasmic levels of dopamine levels continue to 
rise. Under basal conditions, monoamine oxidase (MAO) is able to degrade excess 
cytoplasmic dopamine in order to maintain normal cytoplasmic levels. However studies 
indicate that methamphetamine inhibits this enzyme where excess cytoplasmic dopamine 
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then begins to be oxidized to reactive dopamine metabolites such as cysteinyl-
dopamine.60,64 These reactive dopamine metabolites cause damage to surrounding 
proteins, lipids, and dopaminergic neurons. With a reduction in functioning dopaminergic 
neurons in combination with a decrease in DAT and VMAT2 levels, total baseline 
dopamine levels are decreased leading to the initiation of withdrawal symptoms within 
the user and the resulting urge to continue usage to mitigate these symptoms.63,64 
 
 
Beyond leading to decreased total dopamine levels, methamphetamine initiates 
significant inflammation within the brain. By initially causing cellular damage through 
the development of reactive dopamine metabolites, methamphetamine initiates microglial 
cell activation within various regions of the brain causing inflammation.63,64 
Methamphetamine additionally increases the release and activation of proteinases within 
brain which contributes to the breakdown of the blood-brain barrier. The breakdown of 
the blood-brain barrier allows an influx of inflammatory cytokines, chemokines, and 
macrophages to enter into the brain where an exacerbation of the inflammation created by 
glial activation occurs.64 The excessive neuroinflammation created by these mechanisms 
is believed to contribute to the known differential effects methamphetamine has on 
cognitive function.64,65 
 
Relationship between Sigma-1 Receptors and Methamphetamine 
 
Given that methamphetamine binds to sigma-1 receptors at physiologically relevant 
concentrations, further studies have been conducted in order to better elucidate their 
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relationship with methamphetamine.66 Sigma-1 receptors are thought to have a 
relationship with the effects induced by methamphetamine. Yet unlike cocaine where 
activation of sigma-1 receptors is involved with mediating the physiological effects and 
the resulting neuroplastic changes that are induced, activation of sigma-1 receptors 
mitigates the effects of methamphetamine.67-70  
 
Investigating into methamphetamine’s ability to significantly increase dopamine efflux 
into the synaptic cleft, activation of sigma-1 receptors are capable of reducing this 
efflux.67,68 In one study, neurons loaded with dopamine were voltage-clamped while 
oxidative currents were measured via an amperometric electrode. Administration of 
methamphetamine alone (vehicle) lead to a significant voltage-dependent increase in 
dopamine efflux (Figure 14).67 However pretreatment of these cells with the selective 
sigma-1 receptor agonist, PRE-084, significantly decreased the ability of 
methamphetamine to cause this efflux (Figure 14). By reducing the increased dopamine 
efflux into the synapse caused by methamphetamine, activation of sigma-1 receptors via 
PRE-084 lowered the amount of extracellular dopamine available within the synapse to 
bind to post-synaptic dopamine receptors. With less extracellular dopamine available to 
bind and initiate dopaminergic neuron firing, the augmented sense of reward normally 
experienced with methamphetamine usage would be reduced.  
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Figure 14: PRE-084 Mitigates Methamphetamine-Stimulated Dopamine Efflux. 
Yellow fluorescent protein-dopamine transporter cells were loaded with dopamine in 
order to measure methamphetamine (METH)-stimulated dopamine efflux. The bar graph 
shows the average METH-stimulated dopamine efflux above baseline following 
treatment with vehicle or PRE-084. Sigma-1 receptor activation via PRE-084 
significantly decreases methamphetamine-stimulated efflux compared to vehicle (***, 
p<0.001). One-way ANOVA was performed, N= 4 cells. Adapted from Sambo et al., 
2017.67 
 
 
Beyond decreasing dopamine efflux, both sigma-1 receptor overexpression and activation 
via an agonist demonstrated the ability to decrease methamphetamine-stimulated 
increases in the firing rate of dopaminergic neurons.67,68 Methamphetamine caused a 
significant increase in the firing rate of these neurons above baseline (Figure 15).67 
However in the neurons overexpressing an enhanced yellow fluorescent protein (EYFP)-
tagged sigma receptors or the neurons pretreated with PRE-084, the methamphetamine-
induced increase in firing rate was blocked (Figure 15). Additionally neither the 
overexpression of sigma-1 receptors or pre-treatment with PRE-084 interfered with 
baseline dopaminergic neuron firing in the absence of methamphetamine (Figure 15). 
These results further demonstrate the capability of sigma-1 receptors to be utilized as a 
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means to reduce the methamphetamine-induced increase in dopaminergic neuronal firing 
and the resulting augmented sense of reward felt in a user after administration.  
 
 
 
Figure 15: Effects of Sigma-1 Receptor Overexpression and PRE-084 on 
Methamphetamine-Induced Neuronal Firing Rate. The spontaneous firing activity of 
mouse dopaminergic neurons were recorded at resting membrane potential. The bar 
graph shows spontaneous firing rate (spikes per second) in the control, sigma-1 receptor 
overexpression (σ1R- EYFP), and PRE-084 treatment groups at baseline and after METH 
treatment. Sigma-1 receptor overexpression or use of the sigma-1 receptor agonist, PRE-
084, significantly inhibited METH-induced, DAT-mediated increases in the firing rate of 
dopaminergic neurons (****, p<0.0001). Two-way ANOVA was performed, N=12 neurons. 
Adapted from Sambo et al, 2017. 67 
 
 
In regards to the increase in locomotor activity methamphetamine induces within users, 
further studies have shown the capability of sigma-1 receptor activation in attenuating 
this effect.67,69,70 Pretreatment of saline and administration of 1 mg of methamphetamine 
(Sal/Meth) induced a significant increase in locomotor activity in mice compared to the 
control of pretreatment of saline and administration of saline (Sal/Sal) (Figure 16).69 
However pretreatment of 20mg of the selective sigma-1 receptor agonist, 3-(4-(4-
cyclohexylpiperazin-1-yl)butyl)benzo[d]thiazole-2(3H)-thione (CM156), prior to 
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methamphetamine administration (CM156/METH) significantly reduced the increase of 
locomotor activity back to baseline (Figure 16). This serves as indication that activation 
of sigma-1 receptors can reduce the behavior adaptions invoked by methamphetamine.  
 
 
Figure 16: Effects of CM156 on Reducing Methamphetamine-induced Locomotor 
Activity. Swiss Webster mice were pretreated with an injection of either saline (sal) or 
the sigma-1 receptor agonist, CM156 (20mg/kg), before being administered an injection 
of either methamphetamine (METH) or saline. Locomotor activity, measured in cm, was 
then measured for the following 120 minutes. The mice pre-treated with the CM156 prior 
to being administered methamphetamine retained locomotor activity levels significantly 
lower than the mice who were pre-treated with just saline prior to being administered 
methamphetamine (*, p < 0.05; **p < 0.01; ***p < 0.001).  One-way ANOVA was 
performed. N= 6-11 per group. Adapted from Sambos, 2018.68 
 
Overall activation of sigma-1 receptors via ligands and overexpression of sigma-1 
receptors is capable of attenuating the methamphetamine-induced effects of increased 
dopamine efflux into neuron synapses, increased firing rates of dopaminergic neurons, 
and increased locomotor activity.67-70 While sigma-1 receptors activation and 
overexpression prevent these effects, insights into underlying mechanisms that allow 
sigma-1 receptors to be capable of this action remain limited.   
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DISCUSSION 
The Discovered Relationship Between Sigma-1 Receptors and Substances of Abuse 
 
Reviewing the literature found, evidence dictates that a relationship does exist between 
sigma-1 receptors and the substances of abuse cocaine and methamphetamine.  Given 
that both of these drugs bind to sigma-1 receptors at physiological relevant 
concentrations, there was strong speculation that these receptors were associated with 
enacting the physiological actions of these drugs.43,66 Conducting further research on the 
topic has revealed that the action of sigma-1 receptors differs depending on the substance 
of abuse involved. 32,46,48,50,67-70 
 
Out of the substances of abuse speculated to utilize sigma-1 receptors, cocaine and its 
relationship with sigma-1 receptors was the most researched. From this research, 
underlying mechanisms were discovered that demonstrated sigma-1 receptors role in 
mediating the physiologic effects of cocaine. 32,38,46,48,50  Upon activation, sigma-1 
receptors, by increasing the cholesterol content of the microdomains surrounding of 
DATs are capable of forcing existing DATs from an inward-facing conformation into an 
outward-facing conformation on pre-synaptic neurons, increasing the number of DATs 
available for cocaine to bind and effectively block dopamine reuptake from the neuron 
synaptic cleft.32,44-45 Through this mechanism, sigma-1 receptors assist in allowing 
cocaine to effectively increase extracellular concentrations of dopamine in the synaptic 
cleft leading to increased dopamine receptor binding which mediates the euphoric feeling 
associated with cocaine usage.31,32  Additionally sigma-1 receptors upon activation by 
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cocaine bind to K1.2v channels within the endoplasmic reticulum of nucleus accumbens 
spiny medium neurons and translocate the channels to the plasma membrane.38,46,47 
Through this action, voltage-gated K+ current is increased within these neurons inducing 
a persistent firing rate depression.38,48 With chronic usage of cocaine, long-term firing 
rate depression within the nucleus accumbens mediates a decreased sensitivity of the 
mesolimbic reward pathway, resulting in an individual being unable to experience the 
same level of perceived reward from natural reinforcers as experienced prior to cocaine 
usage.42 Lastly sigma-1 receptors upon activation by cocaine upregulate early genes 
within the brain that are capable of enacting long-term changes to gene and protein 
expression.49 With these changes in gene and protein expressions, individual locomotor 
activity is increased and neuroplastic alterations within the brain occur that are believed 
to further contribute to more permanent decreases in the sensitivity of the mesolimbic 
reward system, leading to withdraw symptoms experienced by users.42,50 The desire to 
reduce these withdraw symptoms then encourages further cocaine usage, creating a cycle 
of dependence where an individual becomes addicted to the substance.42  
 
Compared to cocaine, substantially less studies have been conducted investigating the 
relationship of sigma-1 receptors and methamphetamine. Despite this, most studies 
conducted have identified both sigma-1 receptor overexpression and activation as having 
a neuroprotective effect within the brain against the physiologic effects enacted by 
methamphetamine as opposed to having a mediating role as proven with cocaine usage.67-
70 Evidence shows that sigma-1 receptors are capable of attenuating the 
methamphetamine-induced effects of increased dopamine efflux into neuron synapses, 
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increased firing rates of dopaminergic neurons, and increased locomotor activity.67-70 
Through sigma-1 receptor activation, both the methamphetamine-induced effects that 
lead to desensitization of the mesolimbic reward pathway and the effects that lead to 
behavioral changes are mitigated.67-70 Despite evidence demonstrating these capabilities 
of sigma-1 receptors though, the underlying mechanisms of how sigma-1 receptors are 
responsible for these actions are unclear and consequently further research needs to 
conducted in order to better clarify sigma-1 receptors neuroprotective role in preventing 
methamphetamine addiction. 
 
Sigma-1 Receptors as Potential Therapeutic Targets 
 
Given the proven effectiveness of utilizing sigma-1 receptor antagonists to mitigate the 
effects of cocaine and sigma-1 receptor agonists to mitigate the effects of 
methamphetamine, it is reasonable to consider sigma-1 receptors as pharmacological 
targets for treatment of substance use disorders involving these substances. While 
establishing the benefits of targeting sigma-1 receptors is indeed progress towards 
developing an effective pharmacological intervention for treatment of substance use 
disorders, several factors must be considered before utilizing sigma-1 antagonists and 
agonists as treatment.  
 
One of the first factors to consider about targeting sigma-1 receptors is their prevalence in 
areas of the body beyond the central nervous system. While predominantly prevalent 
within the neurons of the CNS, literature states that sigma-1 receptors are also widely 
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distributed within organs such as the heart, kidney, and liver as well as present within a 
variety of cells ranging from lymphocytes, retinal cells, and even certain cancer cells.71,72 
While the reviewed studies indicate that sigma-1 receptor antagonists and agonists altered 
neuronal activity in the CNS only in the prevalence of cocaine and methamphetamine, 
insufficient research currently exists detailing if this selective action also occurs in the 
other areas of the body where sigma-1 receptors are prevalent. Further research must be 
conducted to evaluate the potential systemic effects of utilizing sigma-1 receptors 
agonists and antagonists given the widespread distribution of sigma-1 receptors 
throughout the body. 
 
Beyond sigma-1 receptors prevalence throughout various regions of the body, the 
interaction of current FDA-approved drugs with sigma-1 receptors must also be 
considered before pharmacologically targeting these receptors. Accumulating evidence 
shows that sigma-1 receptors play a role in the mechanistic action of some therapeutic 
drugs such as selective serotonin reuptake inhibitors (SSRIs), neurosteroids, and 
donepezil, a medication used in the palliative treatment of Alzheimer’s disease.73,74 
Preclinical studies have shown that these drugs act as sigma-1 receptor agonists where 
activation of sigma-1 receptors is believed to contribute to the benefit these drugs provide 
in managing neuropsychiatric disorders.74 This presents the possibility of both sigma-1 
receptors agonists and antagonists altering the efficacy of these classes of drugs and 
leading to potential negative effects. It is therefore clear that further consideration must 
be made when deciding whether to utilize a sigma-1 receptor antagonist or agonist as a 
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therapeutic intervention for an individual suffering from a substance use disorder given 
the possible risk of drug interactions with current neuropsychiatric drugs and the negative 
consequences that could result.  
 
Lastly the effects of long-term usage of sigma-1 receptor antagonists and agonists must 
be considered when contemplating utilization of them as treatment for substance use 
disorders. Current data suggests that sigma-1 receptor activation amplifies pre-existing 
functional mechanisms of neuroprotection against neurologic diseases while dysfunction 
or blockage of these receptors has been linked to the progression of diseases such as 
Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and retinal 
degeneration.75,76 While the data collected supports the use of a sigma-1 receptor agonist 
as treatment for a substance use disorder involving methamphetamine, the data implies 
that utilization of a sigma-1 receptor antagonist for treatment of a substance use disorder 
involving cocaine could potentially lead to the progression of other serious diseases. 
Further research must therefore be conducted about the long-term effects of utilizing 
sigma-1 receptors antagonists in order to better establish the safety of utilizing these 
antagonists as treatment for substance use disorders. Should sigma-1 receptor targeting 
prove to be an effective and safe therapy, this intervention has the potential to serve as 
treatment for the 20.1 million Americans who suffer from a substance use disorder.1   
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CONCLUSION 
 
Substance use disorders are a prominent issue that not only negatively impact the affected 
individual but also the United States as a whole given the associated economic, 
healthcare, and lost productivity costs. However current medical treatments geared 
towards aiding individuals with this disorder are limited and often ineffective. Literature 
suggests that a pharmacological intervention in combination with behavioral therapy will 
be the most effective in treating the addiction symptoms associated with these disorders. 
Yet currently no medication has been approved by the FDA for this indication.  
 
With the relationship revealed between sigma-1 receptors and the substances of abuse, 
cocaine and methamphetamine, sigma-1 receptors show promise as therapeutic targets for 
treatment of substance use disorders. Studies reviewed indicate that through appropriate 
targeting of these receptors the physiological effects induced by cocaine and 
methamphetamine in users can be mitigated, preventing the neuroplastic changes within 
the brain that can lead to substance addiction and the development of substance use 
disorders. While these initial results offer the idea that targeting sigma-1 receptors can be 
an effective therapy, it is clear that variability exists in the interactions sigma-1 receptors 
have with a given substance of abuse given that sigma-1 antagonists mitigate the effects 
induced by cocaine while sigma-1 agonists possess this capability for the effects induced 
by methamphetamine. Further studies should be conducted in order to better understand 
the underlying reasons that cause this variability as perhaps a common action exists 
within the overall mechanisms of interaction between sigma-1 receptors and these 
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substances of abuse. Should a common mechanism of action exist, targeting this 
particular mechanism could potentially serve as a more selective, safer pharmacological 
intervention that avoids the risks associated with generally targeting sigma-1 receptors 
that are distributed widely throughout the body.  
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